Syros Pharmaceuticals Inc (NASDAQ: SYRS) kicked off on Monday, down -5.34% from the previous trading day, before settling in for the closing price of $0.27. Over the past 52 weeks, SYRS has traded in a range of $0.18-$8.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 128.79%. While this was happening, its average annual earnings per share was recorded 73.32%. With a float of $17.39 million, this company’s outstanding shares have now reached $26.83 million.
The extent of productivity of a business whose workforce counts for 68 workers is very important to gauge. In terms of profitability, gross margin is -228.76%, operating margin of -28892.23%, and the pretax margin is -25340.67%.
Syros Pharmaceuticals Inc (SYRS) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Syros Pharmaceuticals Inc is 35.20%, while institutional ownership is 36.36%. The most recent insider transaction that took place on Dec 02 ’24, was worth 10,016. Before that another transaction happened on Nov 25 ’24, when Company’s Director sold 134,713 for $0.27, making the entire transaction worth $35,739. This insider now owns 41,070 shares in total.
Syros Pharmaceuticals Inc (SYRS) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -2.22 earnings per share (EPS), lower than consensus estimate (set at -1.12) by -1.1. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.7 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 73.32% per share during the next fiscal year.
Syros Pharmaceuticals Inc (NASDAQ: SYRS) Trading Performance Indicators
Take a look at Syros Pharmaceuticals Inc’s (SYRS) current performance indicators. Last quarter, stock had a quick ratio of 2.25. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 17.96.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.03, a number that is poised to hit -0.69 in the next quarter and is forecasted to reach -2.05 in one year’s time.
Technical Analysis of Syros Pharmaceuticals Inc (SYRS)
The latest stats from [Syros Pharmaceuticals Inc, SYRS] show that its last 5-days average volume of 3.61 million was superior to 2.38 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 42.16%. Additionally, its Average True Range was 0.22.
During the past 100 days, Syros Pharmaceuticals Inc’s (SYRS) raw stochastic average was set at 1.10%, which indicates a significant decrease from 2.31% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 840.16% in the past 14 days, which was higher than the 375.53% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6830, while its 200-day Moving Average is $4.1424. Now, the first resistance to watch is $0.2731. This is followed by the second major resistance level at $0.2892. The third major resistance level sits at $0.2994. If the price goes on to break the first support level at $0.2468, it is likely to go to the next support level at $0.2366. The third support level lies at $0.2205 if the price breaches the second support level.
Syros Pharmaceuticals Inc (NASDAQ: SYRS) Key Stats
The company with the Market Capitalisation of 7.00 million has total of 26,832K Shares Outstanding. Its annual sales at the moment are 9,940 K in contrast with the sum of -164,570 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -6,400 K.
